{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:22:56Z","timestamp":1775841776974,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.rdc.2009.03.008","type":"journal-article","created":{"date-parts":[[2009,5,28]],"date-time":"2009-05-28T05:12:38Z","timestamp":1243487558000},"page":"163-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Latent Infection and Tuberculosis Disease in Rheumatoid Arthritis Patients"],"prefix":"10.1016","volume":"35","author":[{"given":"Eduardo","family":"Acevedo-V\u00e1squez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dar\u00edo","family":"Ponce de Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Gamboa-C\u00e1rdenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2009.03.008_bib1","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1590\/S0074-02762003000900023","article-title":"Prehistoric tuberculosis in America: adding comments to literature review","volume":"98","author":"Gomez","year":"2002","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.rdc.2009.03.008_bib2","series-title":"[Challenges for diagnosis and treatment for rheumatoid arthritis in Latin America.]","first-page":"349","article-title":"[Tuberculosis as emergent diseases associated to medical treamtment of rheumatoid arthritis.]","author":"Acevedo-Vasquez","year":"2006"},{"key":"10.1016\/j.rdc.2009.03.008_bib3","series-title":"Global tuberculosis control","author":"World Health Organization","year":"2008"},{"key":"10.1016\/j.rdc.2009.03.008_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1055\/s-0028-1085700","article-title":"Global epidemiology of tuberculosis: prospects for control","volume":"29","author":"Lonnroth","year":"2008","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.rdc.2009.03.008_bib5","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1001\/jama.293.22.2767","article-title":"Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally","volume":"293","author":"Dye","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2009.03.008_bib6","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/82139","article-title":"Latent Mycobacterium tuberculosis persistence, patience, and winning by waiting","volume":"6","author":"Manabe","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.rdc.2009.03.008_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.immunol.19.1.93","article-title":"Immunology of tuberculosis","volume":"19","author":"Flynn","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.rdc.2009.03.008_bib8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1359-6101(03)00054-6","article-title":"Chemokines and tuberculosis","volume":"14","author":"Algood","year":"2003","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.rdc.2009.03.008_bib9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.coi.2005.06.006","article-title":"Host innate and Th1 responses and the bacterial factors that control Mycobacterium tuberculosis infection","volume":"17","author":"Salgame","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.rdc.2009.03.008_bib10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0167-5699(98)01438-8","article-title":"Cytokine\/chemokine cascades in immunity to tuberculosis","volume":"20","author":"Orme","year":"1999","journal-title":"Immunol Today"},{"key":"10.1016\/j.rdc.2009.03.008_bib11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/jcpa.2000.0427","article-title":"Lymphocyte subtype in experimentally induced early-stage bovine tuberculous lesions","volume":"124","author":"Cassidy","year":"2001","journal-title":"J Comp Pathol"},{"key":"10.1016\/j.rdc.2009.03.008_bib12","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1128\/IAI.67.7.3571-3579.1999","article-title":"Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium","volume":"67","author":"Ehlers","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.rdc.2009.03.008_bib13","first-page":"379","article-title":"Role of tumor necrosis factor-alpha in Mycobacterium- induced granuloma formation in tumor necrosis factor alpha- deficient mice","volume":"79","author":"Kaneko","year":"1999","journal-title":"Lab Invest"},{"key":"10.1016\/j.rdc.2009.03.008_bib14","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/IAI.69.3.1847-1855.2001","article-title":"Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology","volume":"69","author":"Mohan","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.rdc.2009.03.008_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-\u03b3: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.rdc.2009.03.008_bib16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1146\/annurev.immunol.15.1.749","article-title":"Cellular responses to interferon-\u03b3","volume":"15","author":"Boehm","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.rdc.2009.03.008_bib17","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/09031936.00140007","article-title":"Susceptibility to nontuberculous mycobacterial lung disease","volume":"31","author":"Sexton","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rdc.2009.03.008_bib18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ni1449","article-title":"IL-23 and IL-17 in the establishment of protective pulmonary CD4 (+) T cell responses after vaccination and during Mycobacterium tuberculosis challenge","volume":"8","author":"Khader","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.rdc.2009.03.008_bib19","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.immuni.2008.03.004","article-title":"The biological functions of T helper 17 cell effectors cytokines in inflammation","volume":"28","author":"Ouyang","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.rdc.2009.03.008_bib20","first-page":"361","article-title":"Role of interleukin-6 in the induction of protective T cells during mycobacterial infections in mice","volume":"82","author":"Appelberg","year":"1994","journal-title":"Immunology"},{"key":"10.1016\/j.rdc.2009.03.008_bib21","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1128\/IAI.67.11.5747-5754.1999","article-title":"Interleukin-6 and interleukin-12 participate in induction of a type 1 protective T-cell response during vaccination with a tuberculosis subunit vaccine","volume":"67","author":"Leal","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.rdc.2009.03.008_bib22","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1128\/IAI.68.6.3322-3326.2000","article-title":"Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection","volume":"68","author":"Saunders","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.rdc.2009.03.008_bib23","doi-asserted-by":"crossref","first-page":"7222","DOI":"10.4049\/jimmunol.178.11.7222","article-title":"B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis","volume":"178","author":"Maglione","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.rdc.2009.03.008_bib24","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. A multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2009.03.008_bib25","first-page":"1436","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"30","author":"Carmona","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2009.03.008_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/s10165-004-0281-x","article-title":"Clinical characteristics of Mycobacterium in rheumatoid arthritis patients","volume":"14","author":"Yoshinaga","year":"2004","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.rdc.2009.03.008_bib27","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1136\/ard.2005.047274","article-title":"Elevated risk of tuberculosis in patients with rheumatoid arthritis in Japan","volume":"65","author":"Yamada","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2009.03.008_bib28","doi-asserted-by":"crossref","first-page":"310","DOI":"10.15381\/anales.v67i4.1312","article-title":"[Risk of tuberculosis disease in rheumatoid arthritis patients.]","volume":"67","author":"Gamboa","year":"2006","journal-title":"Anales de la Facultad de Medicina de Montevideo"},{"key":"10.1016\/j.rdc.2009.03.008_bib29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2009.03.008_bib30","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"Seong","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2009.03.008_bib31","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2009.03.008_bib32","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rdc.2009.03.008_bib33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","article-title":"Antirheumatic drugs and the risk of tuberculosis","volume":"43","author":"Brassard","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rdc.2009.03.008_bib34","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.2006.066761","article-title":"Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial","volume":"66","author":"Burmester","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2009.03.008_bib35","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2009.03.008_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials","volume":"68","author":"Salliot","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2009.03.008_bib37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/RHU.0b013e31812e00a1","article-title":"Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists","volume":"13","author":"Settas","year":"2007","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.rdc.2009.03.008_bib38","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1086\/587989","article-title":"Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network","volume":"46","author":"Winthrop","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rdc.2009.03.008_bib39","first-page":"1683","article-title":"Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis","volume":"35","author":"Lutt","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2009.03.008_bib40","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/art.22750","article-title":"Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice","volume":"56","author":"Bigbee","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2009.03.008_bib41","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.23383","article-title":"Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2009.03.008_bib42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1699-258X(06)73063-7","article-title":"Patr\u00f3n de citocinas s\u00e9ricas en pacientes con artritis reumatoide de acuerdo a su reactividad al PPD","volume":"2","author":"Ponce de Le\u00f3n","year":"2006","journal-title":"Reum Clin"},{"key":"10.1016\/j.rdc.2009.03.008_bib43","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2009.03.008_bib44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cyto.2007.09.014","article-title":"IL-17\/Th17 targeting: on the road to prevent chronic destructive arthritis?","volume":"41","author":"Lubberts","year":"2008","journal-title":"Cytokines"},{"key":"10.1016\/j.rdc.2009.03.008_bib45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cyto.2007.11.022","article-title":"IL-23 and IL-17 in tuberculosis","volume":"41","author":"Khader","year":"2008","journal-title":"Cytokines"},{"key":"10.1016\/j.rdc.2009.03.008_bib46","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0531-5565(03)00090-1","article-title":"Immunosenescence, autoimmunity, and rheumatoid arthritis","volume":"38","author":"Weyand","year":"2003","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.rdc.2009.03.008_bib47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ni1033","article-title":"Age-related changes in lymphocyte development and function","volume":"5","author":"Linton","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.rdc.2009.03.008_bib48","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.clim.2007.01.005","article-title":"Analysis of immunosenescence markers in patients with autoimmnune disease","volume":"123","author":"Thewissen","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.rdc.2009.03.008_bib49","first-page":"1141","article-title":"Premature immunosenescence in rheumatoid arthritis","volume":"29","author":"Weyand","year":"2002","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2009.03.008_bib50","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2004.029041","article-title":"Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis","volume":"64","author":"Ponce de Le\u00f3n","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2009.03.008_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.rdc.2009.03.008_bib52","series-title":"Immunology","first-page":"255.5","article-title":"Hypersensitivity type IV","author":"Roitt","year":"1998"},{"key":"10.1016\/j.rdc.2009.03.008_bib53","doi-asserted-by":"crossref","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","article-title":"Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research","volume":"146","author":"Menzies","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2009.03.008_bib54","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","article-title":"Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon \u03b3 assay","volume":"67","author":"Matulis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2009.03.008_bib55","first-page":"776","article-title":"Comparison of an interferon-\u03b3 assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population","volume":"35","author":"Ponce de Leon","year":"2008","journal-title":"J Rheumatol"},{"issue":"RR-15","key":"10.1016\/j.rdc.2009.03.008_bib56","first-page":"49","article-title":"Guidelines for using the QuantiFERON-TB-Gold test for detecting Mycobacterium tuberculosis infection, United States","volume":"54","author":"Mazurek","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.rdc.2009.03.008_bib57","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1378\/chest.07-1995","article-title":"Clinical utility of the QuantiFERON TB-2G test for elderly patients with active tuberculosis","volume":"133","author":"Kobashi","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.rdc.2009.03.008_bib58","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/BOR.0b013e3283025ec2","article-title":"Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases:diagnostic and therapeutic strategies","volume":"20","author":"Keane","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2009.03.008_bib59","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4414\/smw.2007.11939","article-title":"Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy","volume":"137","author":"Beglinger","year":"2007","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.rdc.2009.03.008_bib60","first-page":"683","article-title":"Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California-2002\u20132003","volume":"53","author":"Centers for Disease Control and Prevention","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.rdc.2009.03.008_bib61","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment","volume":"60","author":"British Thoracic Society, Standards of Care Committee","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.rdc.2009.03.008_bib62","first-page":"1","article-title":"Updated recommendations on interferon gamma release assays for latent tuberculosis infection","volume":"34","year":"2008","journal-title":"Can Commun Dis Rep"},{"issue":"Suppl 3","key":"10.1016\/j.rdc.2009.03.008_bib63","first-page":"265","article-title":"Impact of screening for latent TB before initiating anti-TNF therapy in North America and Europe","volume":"64","author":"Perez","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2009.03.008_bib64","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2009.03.008_bib65","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MCP.0b013e3282f9e650","article-title":"Nontuberculous mycobacterial pulmonary disease","volume":"14","author":"Johnson","year":"2008","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.rdc.2009.03.008_bib66","author":"American College of Rheumatology Hotline"},{"key":"10.1016\/j.rdc.2009.03.008_bib67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/art1.10243","article-title":"Experience with etanercept in an academic medical center; are infection rates increased?","volume":"47","author":"Phillips","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2009.03.008_bib68","doi-asserted-by":"crossref","first-page":"944S","DOI":"10.1378\/chest.126.4_MeetingAbstracts.944S","article-title":"Fatal pulmonary nontuberculous mycobacterial infection in a patient receiving etanercept for rheumatoid arthritis","volume":"126","author":"Jaffery","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.rdc.2009.03.008_bib69","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1136\/thx.2005.056952","article-title":"Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept","volume":"62","author":"Maimon","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.rdc.2009.03.008_bib70","first-page":"12","article-title":"Fatal pulmonary Mycobacterium abscessus infection in a patient using etanercept","volume":"65","author":"Thomas","year":"2006","journal-title":"Hawaii Med J"},{"key":"10.1016\/j.rdc.2009.03.008_bib71","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/00365540310017474","article-title":"Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept","volume":"36","author":"Yim","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.rdc.2009.03.008_bib72","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/ncprheum0538","article-title":"Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy","volume":"3","author":"Van Ingen","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.rdc.2009.03.008_bib73","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/rheumatology\/keh700","article-title":"Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab","volume":"44","author":"Marie","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2009.03.008_bib74","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.diagmicrobio.2005.06.006","article-title":"Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use","volume":"53","author":"Mufti","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.rdc.2009.03.008_bib75","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/s10165-004-0360-z","article-title":"Rapidly aggravated Mycobacterium avium infection in a patient with rheumatoid arthritis treated with infliximab","volume":"15","author":"Okubo","year":"2005","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.rdc.2009.03.008_bib76","first-page":"723","article-title":"Mycobacterium fortuitum infection complicating infliximab therapy in rheumatoid arthritis","volume":"24","author":"Boulman","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2009.03.008_bib77","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1128\/AAC.42.9.2336","article-title":"Inhibition of tumour necrosis factor alpha alters resistance to mycobacterium complex avium in mice","volume":"42","author":"Bala","year":"1998","journal-title":"Antimicrobial Agents Chemother"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X0900009X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X0900009X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:06:54Z","timestamp":1760180814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X0900009X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0889857X0900009X"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2009.03.008","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Latent Infection and Tuberculosis Disease in Rheumatoid Arthritis Patients","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2009.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}